thalidomide has been researched along with Retroperitoneal Neoplasms in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Retroperitoneal Neoplasms: New abnormal growth of tissue in the RETROPERITONEAL SPACE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is a promising agent that may exert a therapeutic benefit in HS." | 5.34 | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. ( Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I, 2007) |
| "Castleman disease is a rare lymphoproliferative disorder." | 1.35 | Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris. ( Gonda, A; Illes, A; Miltenyi, Z; Remenyik, E; Tar, I; Toth, J, 2009) |
| "Thalidomide is a promising agent that may exert a therapeutic benefit in HS." | 1.34 | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. ( Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miltenyi, Z | 1 |
| Toth, J | 1 |
| Gonda, A | 1 |
| Tar, I | 1 |
| Remenyik, E | 1 |
| Illes, A | 1 |
| Gergis, U | 1 |
| Dax, H | 1 |
| Ritchie, E | 1 |
| Marcus, R | 1 |
| Wissa, U | 1 |
| Orazi, A | 1 |
| Abidi, MH | 1 |
| Tove, I | 1 |
| Ibrahim, RB | 1 |
| Maria, D | 1 |
| Peres, E | 1 |
1 review available for thalidomide and Retroperitoneal Neoplasms
| Article | Year |
|---|---|
Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Hematopoietic Stem Cell Transplantation; Hist | 2011 |
2 other studies available for thalidomide and Retroperitoneal Neoplasms
| Article | Year |
|---|---|
Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris.
Topics: Adrenal Cortex Hormones; Castleman Disease; Cyclosporine; Female; Humans; Immunomodulation; Immunosu | 2009 |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2007 |